Live Cell Imaging Market

Global Live Cell Imaging Market Size (2023 to 2028)

The global market size for live-cell imaging is predicted to be worth USD 3.5 billion by 2028 from USD 2.27 billion in 2023, growing at a CAGR of 9.02% from 2023 to 2028.

Live cell imaging is a procedure in biomedical studies like cell biology, pharmacology, etc. Live cell imaging is observing a live cell for a certain period. Live cell imaging uses live cell imaging microscopes to follow slow processes of cells, which cannot typically be observed by human perception, like wound healing or fertilization. The live cell microscope is equipped with recording cameras and is connected to software specifically for live cell imaging, which can be used to make notes and observations. The app can also review the captured footage and create time lapses to divide the experimentation results. Fluorescence microscope procedures are also used to picture live cell imaging better. This imaging is commonly performed in incubators where the temperature, CO2 content, and other specifications are maintained for proper imaging of a live cell. 

Impact of COVID-19 on the global live cell imaging market:

Several people died due to the covid-19 epidemic, which started in China and spread worldwide. The pandemic resulted in a recession and substantial economic loss because all businesses and services were shut down. Many productions experienced demand and supply chain disruptions due to the strict lockdown, which led to massive waste output and a loss of individual investment. Many households lost their jobs due to a lack of income, and businesses started to lay off workers to save money. Additionally, the government began disbursing aid payments to people with financial difficulties. The healthcare sector was the market category that was most severely affected.

The COVID-19 pandemic has positively impacted the global live cell imaging market.

The coronavirus became a pandemic because of its unknown nature and origins, which meant that it had no antidote or vaccine. As corona cases kept rising and the death poll continuously grew, the need for developing a vaccine became critical. Many research techniques in biomedical research, including live cell imaging, were used to study the nature of the cells of covid and develop a vaccine for the disease. Therefore, the market has grown due to the assistance of the process with research and development of covid vaccines.

MARKET DRIVERS:

The growth of the live cell imaging market is primarily driven by the rising cases of chronic diseases like cancer which need treatments through research.

In addition, the increasing instances of research and development activities in the biomedical and biosciences fields are helping the market progress. For example, live cell imaging was highly valued during the pandemic due to its ability to observe the live coronavirus. Furthermore, the increasing cases of the adoption of live cell imaging due to the failure of traditional methods and loss of revenue in the pharmaceutical industry are pushing the expansion of the market. The high-content screening techniques of live cell imaging are used in drug analysis and discovery as it is a technical, efficient, and reliable process and helps eliminate the toxins from the drugs. 

Government funding and approvals to support live cell imaging market growth.

The growing investments and funding from government organizations for technological advancements in live cell imaging systems are helping the market grow. In addition, pharmaceutical companies using live cell imaging for drug testing have a higher rate of approvals from government regulators, further increasing the demand for the market. Many researchers trust the research and results of live cell imaging; therefore, major market players are now showing interest in the market's revenue. Especially in emerging countries like India, China, Brazil, etc., the new funding promotes market adaptation. 

Several technological advancements are expected to be made in the field of live cells imaging systems in the future, including self-maintaining incubator chambers, live cell kinetic HCS, tracking of live cells, and better imaging systems, thus promoting the future development of the market and acting as a driver for the revenue in the forecast period. Additionally, it is predicted that there will be a shortage of lab professionals in the future, further increasing the need for such systems.

MARKET RESTRAINTS:

The high costs associated with the high-content screening techniques and the absence of skilled professionals in live cell imaging are expected to restrain the market growth. Additionally, the complexity of the live cell imaging techniques, like keeping the incubator maintained and the cell constantly alive, is expected to be a hindrance to the market's growth. 

REPORT COVERAGE:

This research report on the global live cell imaging market has been segmented and sub-segmented based on the product, application, end-user & region.

Live Cell Imaging Market – By Product:

• Instruments
• Consumables
• Software

Based on the product, the equipment segment led the market in 2022 and is expected to dominate the market during the forecast period because the equipment for live cell imaging can functions without using any hardware, which makes it a cost-effective process. In addition, the equipment brings out the most influential gathering of 3D picture data and helps in having efficient and precise research results. Therefore, the segment's usability and advantages have led to its dominance in the market.

Live Cell Imaging Market – By Application:

• Drug Discovery
• Developmental Biology
• Cell Biology
• Stem Cell Biology

The cell biology segment will dominate the market during the forecast period due to rising molecular research and some developed illumination systems. Furthermore, the cell biology segment is preferred due to its filter application, making it easier to conduct research. Cell biology is also the most prominent study in the life sciences, further promoting the segment's expansion.

Live Cell Imaging Market – By End-User:

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies

Live Cell Imaging Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

The market in North America is expected to gain the most significant revenue during the forecast period due to the rising cost of healthcare, high investment rate, growing senior population, quick adoption of cutting-edge technology, rising demand for live cell imaging, funding for R&D activities for live cell-driven drug discovery, significant investment and financing, supportive drug development regulations, increased product launches, development of personalized medicine, rise in chronic illnesses, and presence of top biotechnology and pharmaceutical companies in countries like the U.S. and Canada are leading to the growth of the market.

The market in Europe and Asia-Pacific is also fast growing due to Government funding programs for stem cell therapy research, an expanding patient population in need of new treatments like stem cell therapy and gene therapy, growing use of these imaging techniques in drug discovery and personalized medicine, the prominence of regenerative medicine research, a rise in drug approvals, preclinical/clinical research, rapid advances in live cell imaging, and a steady increase in cancers and infectious diseases, among other factors, all contribute to the development of the market.

KEY MARKET PARTICIPANTS:

Nikon Instruments Inc., Thermo Fisher Scientific Inc., Molecular Devices LLC, BioTek Instruments Inc., PerkinElmer Inc., Bruker Corporation, General Electric, Olympus Corporation, OLYMPUS CORPORATION, Cytoskeleton Inc., and Merck KGaA are a few of the prominent companies operating in the global live cell imaging market profiled in this report.

RECENT HAPPENINGS IN THIS MARKET:

• In September 2022, Forward.ONE and previous investor Value Creation Capital announced a €5 million investment in Optics11 Life, a fiber optics-based life science instrumentation firm. The money will go toward developing fresh products that use the cutting-edge technology of Optics11 Life for large-scale investigations requiring high-throughput screening of in vitro models and biomaterials. Optics11 Life is an example of how the right team with the right domain expertise can execute a vision like this, and we're excited to welcome the company to our portfolio. "We're firm believers in the power of innovative enabling technology to reshape a market and create new opportunities and fields," said Robin van Boxtel, a partner at Forward.ONE.
• In March 2022, The Netherlands-based CytoSMART Technologies, a pioneer in kinetic live-cell imaging analysis, was acquired by Axion BioSystems, a top provider of life sciences solutions focused on cutting-edge live-cell assay systems. The partnership paves the way for Axion's significant growth in drug development, immuno-oncology, cell-based therapeutics, and stem cell research. For example, over the past 14 years, research on neurological diseases has changed dramatically because of The Maestro, our flagship bioelectronic assay (BEA) platform. Similar work is being done in ground-breaking domains like immunotherapy by our most recent addition to the BEA portfolio, according to Tom O'Brien, President & CEO of Axion BioSystems.